Fingolimod better than interferon beta and GA
Fingolimod better than interferon beta and GA
https://journals.sagepub.com/doi/abs/10 ... 8520918489
Abstract
Background:
Disability progression independent of relapses (PIRA) has been described as a frequent phenomenon in relapsing-remitting multiple sclerosis (RRMS).
Objective:
To compare the occurrence of disability progression in relapse-free RRMS patients on interferon-beta/glatiramer acetate (IFN/GA) versus fingolimod.
Methods:
This study is based on data from the Swiss association for joint tasks of health insurers. Time to relapse and 12-month confirmed disability progression were compared between treatment groups using multivariable Cox regression analysis with confounder adjustment. Inverse-probability weighting was applied to correct for the bias that patients on fingolimod have a higher chance to remain relapse-free than patients on IFN/GA.
Results:
We included 1640 patients (64% IFN/GA, 36% fingolimod, median total follow-up time = 4–5 years). Disease-modifying treatment (DMT) groups were well balanced with regard to potential confounders. Disability progression was observed in 155 patients (8.8%) on IFN/GA and 51 (7.6%) on fingolimod, of which 44 and 23 were relapse-free during the initial DMT, respectively. Adjusted standard regression analysis on all patients indicated that those on fingolimod experience less frequently disability progression compared with IFN/GA (hazard ratio = 0.53 (95% confidence interval = 0.37–0.76)). After bias correction, this was also true for patients without relapses (hazard ratio=0.56 (95% confidence interval = 0.32–0.98).
Conclusion:
Our analysis indicates that fingolimod is superior to IFN/GA in preventing disability progression in both relapsing and relapse-free, young, newly diagnosed RRMS patients.
-
- Similar Topics
- Replies
- Views
- Last post
-
-
biomarker for response to interferon beta-1b
by frodo » Tue Jun 09, 2020 2:38 am » in MS Etiology and Pathogenesis - 0 Replies
- 244 Views
-
Last post by frodo
Tue Jun 09, 2020 2:38 am
-
-
- 0 Replies
- 460 Views
-
Last post by NHE
Tue Jun 30, 2020 8:35 am
-
-
Safety and efficacy of ozanimod vs. fingolimod
by NHE » Sat Apr 25, 2020 2:33 am » in Zeposia (Ozanimod) - 0 Replies
- 188 Views
-
Last post by NHE
Sat Apr 25, 2020 2:33 am
-
-
- 1 Replies
- 320 Views
-
Last post by NHE
Sun May 17, 2020 7:58 pm
-
-
Rituxan better than Fingolimod, Dymethyl fumarate and Natalizumab
by frodo » Tue Aug 11, 2020 2:03 am » in MS Etiology and Pathogenesis - 0 Replies
- 218 Views
-
Last post by frodo
Tue Aug 11, 2020 2:03 am
-
-
- 1 Replies
- 2251 Views
-
Last post by Petr75
Thu Oct 03, 2019 10:54 am
-
-
Biomarker for response to interferon
by frodo » Tue Jan 22, 2019 4:28 am » in MS Etiology and Pathogenesis - 0 Replies
- 729 Views
-
Last post by frodo
Tue Jan 22, 2019 4:28 am
-
-
-
one of the mi-RNA predicts response to interferon
by frodo » Fri Mar 13, 2020 4:50 am » in MS Etiology and Pathogenesis - 0 Replies
- 1985 Views
-
Last post by frodo
Fri Mar 13, 2020 4:50 am
-
-
-
Biomarker for response to interferon: ADC values
by frodo » Thu Aug 20, 2020 12:03 am » in MS Etiology and Pathogenesis - 0 Replies
- 148 Views
-
Last post by frodo
Thu Aug 20, 2020 12:03 am
-